TSE:ONC Oncolytics Biotech Q3 2025 Earnings Report C$14.90 -0.20 (-1.32%) As of 09/3/2025 ProfileEarnings HistoryForecast Oncolytics Biotech EPS ResultsActual EPS-C$0.14Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOncolytics Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncolytics Biotech Announcement DetailsQuarterQ3 2025Date11/12/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Oncolytics Biotech Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY)June 13 at 8:07 AM | theglobeandmail.comOncolytics Biotech (TSE:ONC) Stock Passes Above 200 Day Moving Average - Here's What HappenedJune 13 at 4:13 AM | americanbankingnews.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of the profits are typically already gone. SpaceX insiders bought in at a $20 billion valuation - you're being offered entry at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's supply chain, still priced like Wall Street hasn't noticed. It powers critical infrastructure Musk's operation can't run without. Dylan Jovine is naming it today, free.June 15 at 1:00 AM | Behind the Markets (Ad)Oncolytics Biotech (TSE:ONC) Share Price Passes Below Two Hundred Day Moving Average - Here's WhyJune 5, 2026 | americanbankingnews.comOncolytics Highlights Pelareorep-RAS Combo Preclinical Cancer ResultsJune 2, 2026 | theglobeandmail.comThe Ambrx playbook may be reappearing at OncolyticsMay 28, 2026 | msn.comSee More Oncolytics Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncolytics Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncolytics Biotech and other key companies, straight to your email. Email Address About Oncolytics BiotechOncolytics Biotech (TSE:ONC), a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.View Oncolytics Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationWhy Oracle's 10% Drop May Be Telling the Wrong StorySpotify's "North Star" Outlook Was Music to Investors EarsThis Energy Stock Has Quietly Soared 130% in a Year Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
